Clinical Trial Update: Ibrutinib + Venetoclax in Untreated WM [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of ibrutinib and venetoclax in patients with untreated Waldenström macroglobulinemia, with results posted in April 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom Macroglobulinemia, MYD88 Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-23